ARMP logo

ARMP
Armata Pharmaceuticals Inc

8,213
Mkt Cap
$279M
Volume
92,570.00
52W High
$16.34
52W Low
$1.74
PE Ratio
-1.09
ARMP Fundamentals
Price
$8.46
Prev Close
$7.60
Open
$7.52
50D MA
$10.19
Beta
0.48
Avg. Volume
67,961.05
EPS (Annual)
-$4.80
P/B
-0.99
Rev/Employee
$80,393.44
$506.91
Loading...
Loading...
News
all
press releases
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update PR Newswire LOS...
PR Newswire·7d ago
News Placeholder
More News
News Placeholder
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02 Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02 PR Newswire LOS ANGELES, May 7, 2026 Enables more frequent...
PR Newswire·13d ago
News Placeholder
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
Armata Pharmaceuticals Announces Structural Biology Publication in 'Communications Biology' Armata Pharmaceuticals Announces Structural Biology Publication in 'Communications Biology' PR Newswire LOS...
PR Newswire·16d ago
News Placeholder
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results PR Newswire LOS ANGELES...
PR Newswire·2mo ago
News Placeholder
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025...
PR Newswire·2mo ago
News Placeholder
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for...
PR Newswire·3mo ago
News Placeholder
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus Armata Pharmaceuticals...
PR Newswire·4mo ago
News Placeholder
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates
Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 0.00% and -16.01%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
News Placeholder
Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of -26.24% and -71.95%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
News Placeholder
Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -3.13% and -5.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
<
1
2
...
>

Latest ARMP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.